Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company also develops Collagen Medical Device platform products for nerve, tendon, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
Metrics to compare | OCC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOCCPeersSector | |
---|---|---|---|---|
P/E Ratio | −32.3x | −5.8x | −0.6x | |
PEG Ratio | 4.90 | −0.09 | 0.00 | |
Price/Book | 19.0x | 3.7x | 2.6x | |
Price / LTM Sales | 36.6x | 17.7x | 3.3x | |
Upside (Analyst Target) | - | 299.0% | 39.1% | |
Fair Value Upside | Unlock | −5.8% | 5.3% | Unlock |